• Nuvation Bio launched an underwritten offering of USD 200 million Convertible Senior Notes due 2032.
• Underwriters received a 30-day option to buy up to an additional USD 30 million of notes, lifting potential gross proceeds to USD 230 million.
• Notes mature July 1, 2032; interest payable semiannually; conversion may be settled in cash, Class A shares, or a mix.
• Net proceeds earmarked for capped call costs, full repayment of its senior secured loan agreement, general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-290823), on June 30, 2026, and is solely responsible for the information contained therein.